Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105482 · ClinicalTrials.gov registry record · Phase 2
Targeted Interventions for Weight-Concerned Smokers
A Phase 2 study of Nicotine Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT00105482: Completed Phase 2 study of Nicotine Dependence, sponsored by Yale University.
NCT00105482 is a Phase 2 study of Nicotine Dependence that has completed, run by Yale University. The registered enrollment target is 172 participants, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00105482, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
Weight gain after quitting smoking is an important barrier to treatment for many smokers. This study will test a drug called naltrexone with weight-concerned smokers to investigate whether or not this drug both improves smoking cessation quit rates and minimizes post quit weight gain.
Primary Outcome
Weight change from baseline measured at 26 weeks.
Conditions Studied
Interventions
- DRUG Naltrexone
- BEHAVIORAL Behavioral counseling
- DRUG Transdermal nicotine replacement
Study Locations (1)
Connecticut
- Yale University School of Medicine Substance Abuse Treatment Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00105482 record still lists
NCT00105482 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Naltrexone is the first listed.
NCT00105482 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00105482 about?
NCT00105482 is a clinical study titled "Targeted Interventions for Weight-Concerned Smokers". Weight gain after quitting smoking is an important barrier to treatment for many smokers. This study will test a drug called naltrexone with weight-concerned smokers to investigate whether or not this drug both improves smoking cessation quit rates and minimizes post quit weight gain.
What is the current status of trial NCT00105482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2005-01. Estimated completion is 2009-10.
What conditions does trial NCT00105482 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT00105482?
The interventions under investigation include: Naltrexone (DRUG), Behavioral counseling (BEHAVIORAL), Transdermal nicotine replacement (DRUG).
Who is sponsoring clinical trial NCT00105482?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00105482 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00105482's enrollment target sits among peer trials
172 21st of 67 higher than 47 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia